US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials

Jeanne M. Regnante, Nicole A. Richie, Lola Fashoyin-Aje, Michelle Vichnin, Marvella Ford, Upal Basu Roy, Kenneth Turner, Laura Lee Hall, Evelyn Gonzalez, Nestor Esnaola, Luther T. Clark, Homer C. Adams, Olatunji B. Alese, Keerthi Gogineni, Lorna McNeill, Daniel Petereit, Ify Sargeant, Julie Dang, Coleman Obasaju, Quita HighsmithSimon Craddock Lee, Spencer C. Hoover, Erin L. Williams, Moon S Chen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

PURPOSE: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproportionately low despite a high prevalence of certain cancers in REMG populations. We aimed to identify notable practices used by leading US cancer centers that facilitate REMG participation in cancer trials. METHODS: The National Minority Quality Forum and Sustainable Healthy Communities Diverse Cancer Communities Working Group developed criteria by which to identify eligible US cancer centers-REMGs comprise 10% or more of the catchment area; a 10% to 50% yearly accrual rate of REMGs in cancer trials; and the presence of formal community outreach and diversity enrollment programs. Cancer center leaders were interviewed to ascertain notable practices that facilitate REMG accrual in clinical trials. RESULTS: Eight cancer centers that met the Communities Working Group criteria were invited to participate in in-depth interviews. Notable strategies for increased REMG accrual to cancer trials were reported across five broad themes: commitment and center leadership, investigator training and mentoring, community engagement, patient engagement, and operational practices. Specific notable practices included increased engagement of health care professionals, the presence of formal processes for obtaining REMG patient/caregiver input on research projects, and engagement of community groups to drive REMG participation. Centers also reported an increase in the allocation of resources to improving health disparities and increased dedication of research staff to REMG engagement. CONCLUSION: We have identified notable practices that facilitate increased participation of REMGs in cancer trials. Wide implementation of such strategies across cancer centers is essential to ensure that all populations benefit from advances in an era of increasingly personalized treatment of cancer.

Original languageEnglish (US)
Pages (from-to)e289-e299
JournalJournal of oncology practice
Volume15
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Minority Groups
Ethnic Groups
Clinical Trials
Neoplasms
Community-Institutional Relations
Patient Participation
Resource Allocation
Anniversaries and Special Events
Research
Caregivers
Population
Research Personnel
Interviews

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials. / Regnante, Jeanne M.; Richie, Nicole A.; Fashoyin-Aje, Lola; Vichnin, Michelle; Ford, Marvella; Roy, Upal Basu; Turner, Kenneth; Hall, Laura Lee; Gonzalez, Evelyn; Esnaola, Nestor; Clark, Luther T.; Adams, Homer C.; Alese, Olatunji B.; Gogineni, Keerthi; McNeill, Lorna; Petereit, Daniel; Sargeant, Ify; Dang, Julie; Obasaju, Coleman; Highsmith, Quita; Lee, Simon Craddock; Hoover, Spencer C.; Williams, Erin L.; Chen, Moon S.

In: Journal of oncology practice, Vol. 15, No. 4, 01.04.2019, p. e289-e299.

Research output: Contribution to journalArticle

Regnante, JM, Richie, NA, Fashoyin-Aje, L, Vichnin, M, Ford, M, Roy, UB, Turner, K, Hall, LL, Gonzalez, E, Esnaola, N, Clark, LT, Adams, HC, Alese, OB, Gogineni, K, McNeill, L, Petereit, D, Sargeant, I, Dang, J, Obasaju, C, Highsmith, Q, Lee, SC, Hoover, SC, Williams, EL & Chen, MS 2019, 'US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials', Journal of oncology practice, vol. 15, no. 4, pp. e289-e299. https://doi.org/10.1200/JOP.18.00638
Regnante, Jeanne M. ; Richie, Nicole A. ; Fashoyin-Aje, Lola ; Vichnin, Michelle ; Ford, Marvella ; Roy, Upal Basu ; Turner, Kenneth ; Hall, Laura Lee ; Gonzalez, Evelyn ; Esnaola, Nestor ; Clark, Luther T. ; Adams, Homer C. ; Alese, Olatunji B. ; Gogineni, Keerthi ; McNeill, Lorna ; Petereit, Daniel ; Sargeant, Ify ; Dang, Julie ; Obasaju, Coleman ; Highsmith, Quita ; Lee, Simon Craddock ; Hoover, Spencer C. ; Williams, Erin L. ; Chen, Moon S. / US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials. In: Journal of oncology practice. 2019 ; Vol. 15, No. 4. pp. e289-e299.
@article{4381674bd9cd4de9b6dc79b920ae8d7c,
title = "US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials",
abstract = "PURPOSE: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproportionately low despite a high prevalence of certain cancers in REMG populations. We aimed to identify notable practices used by leading US cancer centers that facilitate REMG participation in cancer trials. METHODS: The National Minority Quality Forum and Sustainable Healthy Communities Diverse Cancer Communities Working Group developed criteria by which to identify eligible US cancer centers-REMGs comprise 10{\%} or more of the catchment area; a 10{\%} to 50{\%} yearly accrual rate of REMGs in cancer trials; and the presence of formal community outreach and diversity enrollment programs. Cancer center leaders were interviewed to ascertain notable practices that facilitate REMG accrual in clinical trials. RESULTS: Eight cancer centers that met the Communities Working Group criteria were invited to participate in in-depth interviews. Notable strategies for increased REMG accrual to cancer trials were reported across five broad themes: commitment and center leadership, investigator training and mentoring, community engagement, patient engagement, and operational practices. Specific notable practices included increased engagement of health care professionals, the presence of formal processes for obtaining REMG patient/caregiver input on research projects, and engagement of community groups to drive REMG participation. Centers also reported an increase in the allocation of resources to improving health disparities and increased dedication of research staff to REMG engagement. CONCLUSION: We have identified notable practices that facilitate increased participation of REMGs in cancer trials. Wide implementation of such strategies across cancer centers is essential to ensure that all populations benefit from advances in an era of increasingly personalized treatment of cancer.",
author = "Regnante, {Jeanne M.} and Richie, {Nicole A.} and Lola Fashoyin-Aje and Michelle Vichnin and Marvella Ford and Roy, {Upal Basu} and Kenneth Turner and Hall, {Laura Lee} and Evelyn Gonzalez and Nestor Esnaola and Clark, {Luther T.} and Adams, {Homer C.} and Alese, {Olatunji B.} and Keerthi Gogineni and Lorna McNeill and Daniel Petereit and Ify Sargeant and Julie Dang and Coleman Obasaju and Quita Highsmith and Lee, {Simon Craddock} and Hoover, {Spencer C.} and Williams, {Erin L.} and Chen, {Moon S}",
year = "2019",
month = "4",
day = "1",
doi = "10.1200/JOP.18.00638",
language = "English (US)",
volume = "15",
pages = "e289--e299",
journal = "Journal of Oncology Practice",
issn = "1554-7477",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials

AU - Regnante, Jeanne M.

AU - Richie, Nicole A.

AU - Fashoyin-Aje, Lola

AU - Vichnin, Michelle

AU - Ford, Marvella

AU - Roy, Upal Basu

AU - Turner, Kenneth

AU - Hall, Laura Lee

AU - Gonzalez, Evelyn

AU - Esnaola, Nestor

AU - Clark, Luther T.

AU - Adams, Homer C.

AU - Alese, Olatunji B.

AU - Gogineni, Keerthi

AU - McNeill, Lorna

AU - Petereit, Daniel

AU - Sargeant, Ify

AU - Dang, Julie

AU - Obasaju, Coleman

AU - Highsmith, Quita

AU - Lee, Simon Craddock

AU - Hoover, Spencer C.

AU - Williams, Erin L.

AU - Chen, Moon S

PY - 2019/4/1

Y1 - 2019/4/1

N2 - PURPOSE: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproportionately low despite a high prevalence of certain cancers in REMG populations. We aimed to identify notable practices used by leading US cancer centers that facilitate REMG participation in cancer trials. METHODS: The National Minority Quality Forum and Sustainable Healthy Communities Diverse Cancer Communities Working Group developed criteria by which to identify eligible US cancer centers-REMGs comprise 10% or more of the catchment area; a 10% to 50% yearly accrual rate of REMGs in cancer trials; and the presence of formal community outreach and diversity enrollment programs. Cancer center leaders were interviewed to ascertain notable practices that facilitate REMG accrual in clinical trials. RESULTS: Eight cancer centers that met the Communities Working Group criteria were invited to participate in in-depth interviews. Notable strategies for increased REMG accrual to cancer trials were reported across five broad themes: commitment and center leadership, investigator training and mentoring, community engagement, patient engagement, and operational practices. Specific notable practices included increased engagement of health care professionals, the presence of formal processes for obtaining REMG patient/caregiver input on research projects, and engagement of community groups to drive REMG participation. Centers also reported an increase in the allocation of resources to improving health disparities and increased dedication of research staff to REMG engagement. CONCLUSION: We have identified notable practices that facilitate increased participation of REMGs in cancer trials. Wide implementation of such strategies across cancer centers is essential to ensure that all populations benefit from advances in an era of increasingly personalized treatment of cancer.

AB - PURPOSE: Participation of racial and ethnic minority groups (REMGs) in cancer trials is disproportionately low despite a high prevalence of certain cancers in REMG populations. We aimed to identify notable practices used by leading US cancer centers that facilitate REMG participation in cancer trials. METHODS: The National Minority Quality Forum and Sustainable Healthy Communities Diverse Cancer Communities Working Group developed criteria by which to identify eligible US cancer centers-REMGs comprise 10% or more of the catchment area; a 10% to 50% yearly accrual rate of REMGs in cancer trials; and the presence of formal community outreach and diversity enrollment programs. Cancer center leaders were interviewed to ascertain notable practices that facilitate REMG accrual in clinical trials. RESULTS: Eight cancer centers that met the Communities Working Group criteria were invited to participate in in-depth interviews. Notable strategies for increased REMG accrual to cancer trials were reported across five broad themes: commitment and center leadership, investigator training and mentoring, community engagement, patient engagement, and operational practices. Specific notable practices included increased engagement of health care professionals, the presence of formal processes for obtaining REMG patient/caregiver input on research projects, and engagement of community groups to drive REMG participation. Centers also reported an increase in the allocation of resources to improving health disparities and increased dedication of research staff to REMG engagement. CONCLUSION: We have identified notable practices that facilitate increased participation of REMGs in cancer trials. Wide implementation of such strategies across cancer centers is essential to ensure that all populations benefit from advances in an era of increasingly personalized treatment of cancer.

UR - http://www.scopus.com/inward/record.url?scp=85064725846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064725846&partnerID=8YFLogxK

U2 - 10.1200/JOP.18.00638

DO - 10.1200/JOP.18.00638

M3 - Article

C2 - 30830833

AN - SCOPUS:85064725846

VL - 15

SP - e289-e299

JO - Journal of Oncology Practice

JF - Journal of Oncology Practice

SN - 1554-7477

IS - 4

ER -